Evidence map›Paper›PMID 40547626›Full record

ArticleACS omega2025

Liver-Skin Microphysiological System for Evaluating Topical Drug Delivery-Induced Liver Injury.

Kun Du, Bei Wang, Ning Yang, Jian Jin, Wei Liu, Feifei Pu, Lili Zou, Zilu Qu, Liuqing Chen

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kun DuHubei Province Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital, Wuhan 430022, China.ORCID https://orcid.org/0009-0007-4600-5463
Bei WangHubei Province Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital, Wuhan 430022, China.
Ning YangDepartment of Medical Equipment, Wuhan No. 1 Hospital, Wuhan 430022, China.
Jian JinDepartment of Medical Equipment, Wuhan No. 1 Hospital, Wuhan 430022, China.
Wei LiuHubei Province Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital, Wuhan 430022, China.
Feifei PuDepartment of Academic Research, Wuhan No. 1 Hospital, Wuhan 430022, China.
Lili ZouInstitute of Biological and Medical Engineering, National Engineering Research Center for Healthcare Devices, Guangdong Academy of Sciences, Guangzhou 510632, China.
Zilu QuHubei Province Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital, Wuhan 430022, China.
Liuqing ChenHubei Province Key Laboratory of Skin Infection and Immunity, Wuhan No. 1 Hospital, Wuhan 430022, China.ORCID https://orcid.org/0000-0002-8398-4652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury is the main cause of acute liver failure and has become a major health problem. Nowadays, topical and transdermal drug delivery has appeared as a popular approach to deliver drugs, and its risk of inducing hepatotoxicity requires careful evaluation before approval for application to humans. To date, hepatotoxicity resulting from topical administration has rarely been studied due to the lack of effective research models. Here, a highly biomimetic liver-skin microphysiological system (LS-MPS) was developed, providing a dynamic and physiologically similar microenvironment to mimic in vivo liver, skin, and cyclic flow between them. The three-dimensional (3D) liver microtissue and 3D skin microtissue were successfully established on the LS-MPS. The skin microtissue showed high cell viability and physiologically similar dermal and epidermal layers. More importantly, the barrier and permeability functions of skin were maintained for long-term culture. The 3D liver microtissue showed high cell viability, biomimetic cell arrangement, and active metabolic function. In addition, the LS-MPS was applied to evaluate the topical delivery of drug-induced liver injury, demonstrating its potential in drug safety testing. Thus, this study provides a promising platform to assess complex drug toxicity, which contributes to the development of new drugs.

Identifiers

PMID40547626
PMCPMC12177747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.